1. according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). 2. known hypersensitivity to omegaven® or any of the ingredients. 3. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. 4. pregnancy and breastfeeding.

1. according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). 2. known hypersensitivity to omegaven® or any of the ingredients. 3. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. 4. pregnancy and breastfeeding.

according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). known hypersensitivity to omegaven® or any of the ingredients. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. pregnancy and breastfeeding.

according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). known hypersensitivity to omegaven® or any of the ingredients. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. pregnancy and breastfeeding.

1. according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). 2. known hypersensitivity to omegaven® or any of the ingredients. 3. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. 4. pregnancy and breastfeeding.

1. according to omegaven® contraindications (serious bleeding disorders, acute life-threatening condition, including acute shock, acute myocardial infarction, acute stroke, acute emboli, and coma). 2. known hypersensitivity to omegaven® or any of the ingredients. 3. participation in any clinical research study evaluating an investigational medicinal product (imp) within 3 months prior to screening. 4. pregnancy and breastfeeding.